San Diego-based CureScience Institute, a non-profit organization dedicated to accelerating novel curative therapies, disclosed on Tuesday that Dr Boris Reznik has been appointed as an Advisory Board member.
Dr Reznik is chairman of Venvalo Group, venture value optimization firm and is a veteran of several startups.
According to CureScience Institute, Dr Reznik has a strong track record of building companies across a diverse set of technologies-based industries, primarily focused on biomedical sciences.
CEO of CureScience Institute, Dr Shashaanka Ashili, commented: "I am delighted to welcome Dr Reznik to our Advisory Board," adding "He brings a unique experience in accelerating drug and device development for life sciences companies. We at CureScienceTM look forward to benefiting from Dr Reznik's counsel as we work towards developing personalized therapeutic approaches."
Crossject advances paediatric development of ZEPIZURE Junior for epilepsy crisis management
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Tissue Regenix secures CE and UKCA certifications for OrthoPure XT
Terumo Corporation expands stroke portfolio in EMEA with SOFIA Flow 88 catheter launch
Crossject advances ZENEO manufacturing with scalable aseptic filling module ahead of product rollout
ZYLOX Unicorn Vascular Closure Device approved in Indonesia
Mindray unveils BeneVision V Series at Euroanaesthesia 2025, advancing precision monitoring
Unicon Pharma and VRR Life Sciences partner support digital transformation in life sciences
Median Technologies submits 510(k) application for eyonis LCS lung cancer screening software